The lung immune prognostic index stratifies the occurrence of checkpoint inhibitor pneumonitis in advanced non-small cell lung cancer patients: a multi-institutional cohort study.

IF 6.8 1区医学 Q1 ONCOLOGY

British Journal of Cancer Pub Date : 2025-08-15 DOI:10.1038/s41416-025-03124-z

Bingxin Gong, Yusheng Guo, Qi Wan, Jie Lou, Guisheng Zhang, Yi Li, Feng Pan, Lian Yang

{"title":"The lung immune prognostic index stratifies the occurrence of checkpoint inhibitor pneumonitis in advanced non-small cell lung cancer patients: a multi-institutional cohort study.","authors":"Bingxin Gong, Yusheng Guo, Qi Wan, Jie Lou, Guisheng Zhang, Yi Li, Feng Pan, Lian Yang","doi":"10.1038/s41416-025-03124-z","DOIUrl":null,"url":null,"abstract":"Background: Lung immune prognostic index (LIPI) is associated with survival outcomes in patients with non-small cell lung cancer (NSCLC) receiving immunotherapy, but the association with the occurrence of checkpoint inhibitor pneumonitis (CIP) is unclear.Methods: We retrospectively included 1824 patients with advanced NSCLC who received immune checkpoint inhibitors (ICIs) at two institutions. Cox regression analysis and cumulative incidence curve were used to evaluate the predictive value of LIPI. Additionally, we performed competing risk analysis using Fine-Gray regression and cumulative incidence curves.Results: During a median follow-up of 15 months, 99 patients developed CIP. Compared with the good LIPI group, the intermediate LIPI group (HR 1.87, P = 0.007) and poor LIPI group (HR 4.39, P < 0.001) had a higher risk of CIP. Furthermore, we found LIPI was an independent predictor for intermediate-grade CIP (intermediate LIPI: HR 2.11, P = 0.056; poor LIPI: HR 4.51, P = 0.002) and high-grade CIP (intermediate LIPI: HR 6.94, P = 0.014; poor LIPI: HR 44.01, P < 0.001), but not for low-grade CIP (intermediate LIPI: HR 1.31, P = 0.392; poor LIPI: HR 0.72, P = 0.656). Similar results were obtained after competing risk analysis.Conclusions: LIPI grade shows potential in predicting the risk of CIP during immunotherapy and could be valuable in clinical management.","PeriodicalId":9243,"journal":{"name":"British Journal of Cancer","volume":" ","pages":""},"PeriodicalIF":6.8000,"publicationDate":"2025-08-15","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"British Journal of Cancer","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1038/s41416-025-03124-z","RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q1","JCRName":"ONCOLOGY","Score":null,"Total":0}

引用次数: 0

Abstract

Background: Lung immune prognostic index (LIPI) is associated with survival outcomes in patients with non-small cell lung cancer (NSCLC) receiving immunotherapy, but the association with the occurrence of checkpoint inhibitor pneumonitis (CIP) is unclear.

Methods: We retrospectively included 1824 patients with advanced NSCLC who received immune checkpoint inhibitors (ICIs) at two institutions. Cox regression analysis and cumulative incidence curve were used to evaluate the predictive value of LIPI. Additionally, we performed competing risk analysis using Fine-Gray regression and cumulative incidence curves.

Results: During a median follow-up of 15 months, 99 patients developed CIP. Compared with the good LIPI group, the intermediate LIPI group (HR 1.87, P = 0.007) and poor LIPI group (HR 4.39, P < 0.001) had a higher risk of CIP. Furthermore, we found LIPI was an independent predictor for intermediate-grade CIP (intermediate LIPI: HR 2.11, P = 0.056; poor LIPI: HR 4.51, P = 0.002) and high-grade CIP (intermediate LIPI: HR 6.94, P = 0.014; poor LIPI: HR 44.01, P < 0.001), but not for low-grade CIP (intermediate LIPI: HR 1.31, P = 0.392; poor LIPI: HR 0.72, P = 0.656). Similar results were obtained after competing risk analysis.

Conclusions: LIPI grade shows potential in predicting the risk of CIP during immunotherapy and could be valuable in clinical management.

查看原文本刊更多论文

肺免疫预后指数对晚期非小细胞肺癌患者中检查点抑制剂肺炎的发生进行分层：一项多机构队列研究。

背景：肺免疫预后指数（LIPI）与接受免疫治疗的非小细胞肺癌（NSCLC）患者的生存结局相关，但与检查点抑制剂肺炎（CIP）发生的关系尚不清楚。方法：我们回顾性地纳入了1824例在两家机构接受免疫检查点抑制剂（ICIs）治疗的晚期非小细胞肺癌患者。采用Cox回归分析和累积发生率曲线评价LIPI的预测价值。此外，我们使用Fine-Gray回归和累积发生率曲线进行竞争风险分析。结果：在15个月的中位随访期间，99例患者发生了CIP。与LIPI良好组相比，LIPI中度组（HR 1.87, P = 0.007）和较差组（HR 4.39， P）结论：LIPI分级在免疫治疗期间预测CIP风险有潜力，对临床管理有价值。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

British Journal of Cancer 医学-肿瘤学

CiteScore

15.10

自引率

1.10%

发文量

383

审稿时长

6 months

期刊介绍： The British Journal of Cancer is one of the most-cited general cancer journals, publishing significant advances in translational and clinical cancer research.It also publishes high-quality reviews and thought-provoking comment on all aspects of cancer prevention,diagnosis and treatment.